Elicio Therapeutics, Inc. (ELTX) is an immuno-oncology company dedicated to elevating immunotherapy by producing responses to different types of treatment that remain inaccessible until now. The company was founded in March 2019 and is headquartered in Cambridge, Massachusetts, United States. Committed to harnessing the full power of the immune system to defeat cancer and other devastating diseases, Elicio Therapeutics use its strategic knowledge of the relationship between the lymph nodes, the integral power plants of the immune system, and the AMP molecule that acts as their GPS coordinate.
Primarily, ELTX has built a unique approach named the Amphiphile platform. This concept notably involves merging the AMP molecule with different types of therapy, creating biologically synergistic therapies that target key lymph nodes. By significantly amplifying the immune response and controlling its activity, this method can potentially revolutionize immunotherapy in various ways, from vaccines to cell therapy to combinations of treatments.
One of the core products, ELTX-02, is a lymph node targeted amphiphile vaccine that combines AMP-PD1 and AMP-CEA (mRNA). These two key products are utilized to stimulate the immune response in various cancer types, including lung and colorectal cancers respectively. Another key product, ELTX-03, follows a similar approach but targets lymphoma with personalized neoantigen vaccines.
ELTX's core strategy focuses on producing disruptive technologies in order to unlock the potential of the immune system, specifically utilizing the lymph node to instigate responses that have been previously unreachable with conventional methods. This emphasis on innovation and continual research to improve patient outcomes makes ELTX a cutting-edge player in the field of immuno-oncology.
The robust scientific foundation drives the company's conviction in its unique potential of combining immunotherapy treatment with the lymph nodes. As such, Elicio Therapeutics, Inc. stands as a promising institution, breaking the conventional norms of tackling cancer and other diseases by developing groundbreaking innovations. The consistent focus on research and development and the shared mission of improving lives make ELTX a company to watch in the future of healthcare.